NeoVolta FY26 Revenue Up 58%, but Sequential Collapse After Q1 Raises Red Flags

What happened

NeoVolta reported fiscal 2026 revenue of $13.3 million, a 58% increase year-over-year, alongside progress on its U.S. BESS manufacturing facility and a new SK ON collaboration for domestic cell supply from 2027-2031. However, the company had already booked $6.65 million in revenue in Q1 FY26, implying the remaining three quarters generated only $6.65 million combined, or an average of $2.2 million per quarter, a roughly 67% sequential decline from the Q1 peak. That collapse contradicts the narrative of accelerating hypergrowth and suggests demand from key dealers may have slowed sharply or that earlier sales were lumpy and unsustainable. The SK ON agreement, while strategically important, is long-dated and does not address the immediate funding and liquidity pressures highlighted in previous filings, including high-cost short-term debt and minimal cash reserves. Overall, the results reinforce concerns that the company's growth is volatile and that the stock's rich valuation is not supported by fundamental momentum.

Implication

The sequential revenue collapse following Q1 indicates that NeoVolta's hypergrowth may have been driven by one-time channel loading or large orders, not underlying demand. The SK ON supply agreement and Georgia manufacturing progress are positive but likely years away from contributing to revenue, and they do not alleviate the company's critical dependence on expensive receivables financing and a 16% credit line. With net losses likely widening for the full year and cash remaining tight, the risk of further dilutive financing is elevated, supporting the bear case with implied value near $1.75. The stock's current valuation, still around $3.52 per the last report, appears disconnected from fundamentals, and even the base case value of $3.25 assumes revenue roughly doubles over two years, which now seems optimistic given the Q2-Q4 performance. Until there is clear evidence of reaccelerating quarterly revenue and margin improvement, investors should trim positions and wait for a more attractive entry below $2.25.

Thesis delta

The FY26 full-year results materially weaken the bull case by revealing a severe sequential decline in revenue after Q1, undermining the assumption of sustained hypergrowth. The base case now appears overly optimistic, as the company's ability to even achieve modest sequential growth is in question. We lower the probability of the bull scenario and increase the probability of the bear scenario, reinforcing the 'POTENTIAL SELL' rating and suggesting a trim above $4.50 if the stock rallies on this news.